These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1780694)

  • 1. Tumor-associated trypsin inhibitor (TATI) in benign and malignant gastric disease.
    Loizate Toricaguena A; Lamiquiz Vallejo A; Dominguez Merru-Urrutia MJ; Legorburu Escudero JF
    Scand J Clin Lab Invest Suppl; 1991; 207():59-62. PubMed ID: 1780694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-associated trypsin inhibitor, TATI, in gastrointestinal cancer and related benign diseases.
    Piantino P; Arosaio E
    Scand J Clin Lab Invest Suppl; 1991; 207():67-9. PubMed ID: 1780697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-associated trypsin inhibitor in pancreatic diseases.
    Aroasio E; Piantino P
    Scand J Clin Lab Invest Suppl; 1991; 207():71-3. PubMed ID: 1723534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242.
    Pasanen P; Eskelinen M; Kulju A; Penttilä I; Janatuinen E; Alhava E
    Scand J Clin Lab Invest; 1995 Apr; 55(2):119-24. PubMed ID: 7667604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening.
    Järvisalo J; Hakama M; Knekt P; Stenman UH; Leino A; Teppo L; Maatela J; Aromaa A
    Cancer; 1993 Mar; 71(6):1982-8. PubMed ID: 8443749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-associated trypsin inhibitor (TATI) in patients with colorectal carcinoma. A critical comparison with CEA.
    Catarino M; Conde R
    Scand J Clin Lab Invest Suppl; 1991; 207():43-6. PubMed ID: 1780689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer-associated antigen CA 195 in patients with mucinous ovarian tumours: a comparative analysis with CEA, TATI and CA 125 in serum specimens and cyst fluids.
    de Bruijn HW; ten Hoor KA; Boonstra H; Marrink J; Krans M; Aalders JG
    Tumour Biol; 1993; 14(2):105-15. PubMed ID: 8392219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour-associated trypsin inhibitor, carcinoembryonic antigen and acute-phase reactant proteins CRP and alpha1-antitrypsin in patients with gastrointestinal malignancies.
    Solakidi S; Dessypris A; Stathopoulos GP; Androulakis G; Sekeris CE
    Clin Biochem; 2004 Jan; 37(1):56-60. PubMed ID: 14675563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder.
    Pectasides D; Bafaloucos D; Antoniou F; Gogou L; Economides N; Varthalitis J; Dimitriades M; Kosmidis P; Athanassiou A
    Am J Clin Oncol; 1996 Jun; 19(3):271-7. PubMed ID: 8638540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-associated trypsin inhibitor (TATI) in the diagnosis of lung cancer.
    Pecchio F; Rapellino M; Baldi S; Casali V; Libertucci D; Coni F
    Scand J Clin Lab Invest Suppl; 1991; 207():63-4. PubMed ID: 1780695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of TATI and other markers in solid tumors.
    Taccone W; Mazzon W; Belli M
    Scand J Clin Lab Invest Suppl; 1991; 207():25-32. PubMed ID: 1780686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum levels of tumor-associated trypsin inhibitor (TATI) in benign and malignant gynecological diseases.
    Torre GC; Rembado R; Barbetti V; Vigliercio GP; Foglia M; Calabrese A; Corongiu F
    Scand J Clin Lab Invest Suppl; 1991; 207():15-8. PubMed ID: 1780684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Determination of tumor-associated trypsin inhibitor (TATI) in subjects with gastrointestinal diseases. Preliminary data].
    Piantino P; Mosso R; Polloni R; Cerchier A; Gennaretti G; Daziano E
    Minerva Med; 1989 Mar; 80(3):199-203. PubMed ID: 2717042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-associated trypsin inhibitor (TATI) and tumor-associated trypsin-2 (TAT-2) predict outcomes in gastric cancer.
    Kasurinen A; Laitinen A; Kokkola A; Stenman UH; Böckelman C; Haglund C
    Acta Oncol; 2020 Jun; 59(6):681-688. PubMed ID: 32124669
    [No Abstract]   [Full Text] [Related]  

  • 15. Postoperative CEA is a better prognostic marker than CA19-9, hCGβ or TATI after resection of colorectal liver metastases.
    Peltonen R; Österlund P; Lempinen M; Nordin A; Stenman UH; Isoniemi H
    Tumour Biol; 2018 Jan; 40(1):1010428317752944. PubMed ID: 29378497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of tumor-associated trypsin inhibitor (TATI) with CA125 as a marker for diagnosis and monitoring of epithelial ovarian cancer.
    Gadducci A; Ferdeghini M; Rispoli G; Prontera C; Bianchi R; Fioretti P
    Scand J Clin Lab Invest Suppl; 1991; 207():19-24. PubMed ID: 1780685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer.
    Medl M; Ogris E; Peters-Engl C; Leodolter S
    Br J Cancer; 1995 May; 71(5):1051-4. PubMed ID: 7734298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of CEA, CA 19-9, CA-50, CA-195, and TATI with special reference to pancreatic disorders.
    Masson P; Pålsson B; Andren-Sandberg A
    Int J Pancreatol; 1991 May; 8(4):333-44. PubMed ID: 1791319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-associated trypsin inhibitor (TATI) in pleural effusions.
    Rapellino M; Pecchio F; Baldi S; Adamo MR; Macri M; Ricardi G
    Scand J Clin Lab Invest Suppl; 1991; 207():47-9. PubMed ID: 1780690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour-associated trypsin inhibitor and renal cell carcinoma.
    Meria P; Toubert ME; Cussenot O; Bassi S; Janssen T; Desgrandchamps F; Cortesse A; Schlageter MH; Teillac P; Le Duc A
    Eur Urol; 1995; 27(3):223-6. PubMed ID: 7601186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.